Dennis Cho’s June 2026 Twist Bioscience Sale: Insider Selling Tumbles Amid 17% Weekly Rally
Insider selling at Twist Bioscience: Dennis Cho’s 14k-share sale signals routine liquidity, not a warning, amid strong biotech growth.
3 minutes to read
TWIST BIOSCIENCE CORP
Twist Bioscience Insider Sales: CEO & SVP Sell to Cover, Stock Stays Bullish Amid Routine RSU Tax Moves
Twist Bioscience insider sales show routine tax‑cover moves, not a sign of pessimism—investors can still chase its 147% YTD growth.
4 minutes to read
CFO Laponis Adam Sells 4,000 Shares at $70, 27% of Holdings Vanish in Twist Bioscience Insider Reshuffle
Discover why CFO Laponis Adam’s recent Twist Bioscience stock sales might signal a strategic reshuffle, and what it means for investors.
3 minutes to read
Twist Bioscience Insider Trading: Starovasnik’s 500-Share Sale Is a Routine Rebalancing, Not a Warning
Insider sale by Melissa Starovasnik at Twist Bioscience is a planned 10b5‑1 liquidity move, not a bearish signal, reflecting routine portfolio rebalancing while insiders remain confident in the biotech’s growth trajectory.
3 minutes to read
Twist Bioscience Insider Trades: CEO and CFO Sell‑to‑Cover Stocks as RSU Vesting Continues—No Red Flag for Investors
Twist Bioscience insider sales: a routine sell‑to‑cover move, not a distress signal—investors see tax‑withholding, not major shift.
3 minutes to read
CFO Laponis Adam Sells 4,000 Twist Shares in Quiet, Rule‑Based Move – Stock Remains Bullish Despite Insider Liquidation
How CFO Laponis Adam’s $60.00 share sale reflects steady cash‑flow planning, not a market‑timed move – insights for Twist Bioscience investors.
3 minutes to read
CFO Adam’s April 3,000‑Share Sale at $55: A Routine Move Amid Twist Bioscience’s Bull Run
Insider selling at Twist Bioscience: CFO’s small April sale reflects routine liquidity, not a red flag, amid strong growth and robust fundamentals.
3 minutes to read
Director Starovasnik Offloads $51K Shares as Twist Bioscience Skyrockets 7.5% This Week—No Alarm, Just Routine Liquidity Event
Insight: Twist Bioscience insider Melissa Starovasnik sells 1,000 shares at $51 in a bullish trend, showing normal liquidity amid rising investor confidence.
2 minutes to read
Twist Bioscience Director Chess Executes Strategic Buy‑Sell Play: $11.89 Discount Sale Followed by $47.00 Premium Purchase Highlights Confidence in Synthetic DNA Future.
Discover how Twist Bioscience insiders use 10b‑5‑1 plans to balance liquidity and bullish positions—insightful analysis for savvy investors.
4 minutes to read
Twist Bioscience Exec Sells 2,184 Shares for Tax Cover Just After New Kit Launch — What It Means for Investors
Twist Bioscience’s Feb 13 sell‑to‑cover by CHESS RObert is a routine tax‑cover move, minimal dilution, but highlights insider activity around its new library kit launch. Click for details.
3 minutes to read